Core Insights - The Shandong provincial government has made significant progress in building a technology-driven economy during the "14th Five-Year Plan" period, with a focus on enhancing regional innovation capabilities and increasing R&D investment [1][2][3] R&D Investment - Shandong's total R&D investment has exceeded 259.73 billion yuan during the "14th Five-Year Plan," with an annual growth rate of 11.5%, surpassing the national average by 1 percentage point [1] - The R&D intensity reached 2.64%, exceeding the planned target by 0.04 percentage points [1] Innovation Platforms - The province has accelerated the construction of a technology innovation platform system, with the approval of 1 national laboratory and 36 national key laboratories, leading the nation in the number of local laboratories [2] - Shandong has initiated the construction of major scientific infrastructure, accounting for 1/7 of the national total, and has established several high-level technology innovation platforms [2] Key Technological Achievements - Shandong has made significant breakthroughs in core technologies, with 138 major innovative achievements recognized, including the world's first fourth-generation nuclear power plant and the largest solid rocket [3] - The province has also achieved global leadership in various scientific fields, contributing to national technological self-reliance [3] Strengthening Enterprise Innovation - The number of technology-based small and medium-sized enterprises has increased from 18,000 to 50,000, marking a growth of 175% [4] - High-tech enterprises have risen from 14,000 to 35,000, a 150% increase, with high-tech industries accounting for 55.31% of the province's industrial output [4] Public Benefit from Technology - Shandong has focused on public health, achieving breakthroughs in innovative drugs and significantly increasing the number of new drug approvals [5] - The province has also made strides in agricultural innovation, with a high coverage rate of improved crop varieties contributing to food security [5] Innovation Ecosystem - Shandong has optimized its innovation ecosystem across various sectors, fostering a supportive environment for enterprises and talent [6] - The province has established international cooperation platforms and is working towards becoming a significant technology innovation center in the country [6]

Group 1: Traditional Industry Transformation - Shandong Province has accelerated the upgrade of traditional industries, with a focus on high-end quality and cluster development, resulting in the transfer of 23.56 million tons of crude steel capacity and the integration of 26.96 million tons of refining capacity [1] - The proportion of crude steel capacity along the coast has increased from less than 25% to 53% [1] - The province has implemented over 12,000 technical reform projects worth more than 5 million yuan each year, with advanced capacity in key industries exceeding 40% and a digital transformation coverage rate of 95.1% among industrial enterprises [1] Group 2: Emerging Industry Development - The number of high-tech enterprises in Shandong has surpassed 35,000, with over 50,000 technology-based SMEs, ranking third in the country [2] - The establishment of R&D institutions has reached a historical high of 16,000, accounting for 38.9% of all industrial enterprises, an increase of 25.6 percentage points since 2020 [2] - New emerging industries have maintained double-digit growth, with significant contributions from strategic emerging industries and future industries [2] Group 3: Digital Economy Advancement - Shandong has invested over 10 billion yuan annually in 5G infrastructure, establishing 266,000 5G base stations and ranking second in the number of gigabit cities nationwide [3] - The province has built three major computing power hubs, with intelligent computing accounting for over 50% of the total [3] - Shandong has cultivated 18 national-level digital leading enterprises and 46 national-level industrial internet platforms, both ranking first in the country [3]

中经记者 苏浩 卢志坤 北京报道 "'用科技表达我们的爱'，这不仅是齐鲁制药的企业使命，更是贯穿我们发展的精神主线。在'健康中国 2035'和全球'人人享有健康'愿景的指引下，我们深知医药企业肩负的重任。"2025年9月23日—24日，由 《中国经营报》主办的"绿色引领 重塑未来——2025中国企业可持续发展行动大会"上，齐鲁制药集团 副总裁郭传珍如是表示，并分享了集团如何"用科技表达爱"的实践与思考。 （图为齐鲁制药集团副总裁 郭传珍） 郭传珍介绍称，在追求健康中国的道路上，医药企业扮演着关键角色。齐鲁制药始终秉承"大医精诚， 家国天下"核心价值观，创新性构建了CARE社会理念模型，将可持续发展、科技创新、绿色运营、社 会贡献等理念深度嵌入企业运行全价值链，积极创造经济、社会、环境协同发展的综合价值。集团建有 11大生产基地、中美联动6大研发中心，产品覆盖生命健康、植物保护、动物保健三大板块；先后10次 跻身中国医药工业百强前十，2023、2024连续两年位列第三位。 科技创新，守护生命尊严 生命至上，创新不止。医药研发高投入、高风险，但对患者而言，每一款创新药都意味着新生的希望。 郭传珍表示，齐鲁制药持续 ...

Group 1 - The collaboration between Qilu Pharmaceutical and the National Natural Science Foundation of China (NSFC) involves the establishment of a joint fund of 99 million yuan to address challenges in the pharmaceutical industry [1][5] - The NSFC aims to promote the development of the national innovation system through partnerships with enterprises, emphasizing the importance of foundational research for subsequent industrial breakthroughs [3][5] - Qilu Pharmaceutical will contribute 30 million yuan annually for three years, totaling 90 million yuan, while the NSFC will match with 3 million yuan per year, amounting to 9 million yuan over the same period [5] Group 2 - The partnership will focus on five key areas: immune disorders, abnormal cell proliferation, gene mutations, metabolic disorders, and neurological diseases, supporting young scientists in their research [5][7] - Qilu Pharmaceutical has a strong track record in innovation, with over 320 products launched and 80 innovative drug projects currently in development, ranking third in the China Pharmaceutical Industry Top 100 [7][9] - The company has established six R&D platforms and employs a dedicated team of 5,000, with R&D investment accounting for 12% of sales revenue, totaling over 20 billion yuan during the 14th Five-Year Plan period [7][9] Group 3 - Qilu Pharmaceutical has over 80 national class I innovative drug projects, with more than 20 in clinical trials, including notable drugs for lung cancer and a global first combination antibody drug [9] - The company aims to leverage this collaboration to enhance the management of funds, organization, and projects, transitioning the biopharmaceutical industry from a follower to a leader [9]